| Patent application number | Description | Published |
|---|
| 20100009863 | METHOD FOR ENGINEERING T-CELL RECEPTORS - The present invention provides a method for engineering a T-cell receptor domain polypeptide comprising at least one modification in a structural loop region of said T-cell receptor domain polypeptide and determining the binding of said T-cell receptor domain polypeptide to an epitope of an antigen, wherein the unmodified T-cell receptor domain polypeptide does not significantly bind to said epitope, comprising the steps of providing a nucleic acid encoding a T-cell receptor domain polypeptide comprising at least one structural loop region, modifying at least one nucleotide residue of at least one of said structural loop regions, transferring said modified nucleic acid in an expression system, expressing said modified T-cell receptor domain polypeptide, contacting the expressed modified T-cell receptor domain polypeptide with said epitope and determining whether said modified T-cell receptor domain polypeptide binds to said epitope. The present invention also covers modified T cell receptor domain polypeptides obtained by said method and their use and libraries containing said modified T cell receptor domain polypeptides. | 01-14-2010 |
| 20100029497 | METHOD FOR ENGINEERING IMMUNOGLOBULINS - The present invention relates to a method for engineering an immunoglobulin comprising a variable domain and at least one modification in at least two structural loops of said immunoglobulin and determining the binding of said immunoglobulin to an epitope of an antigen, wherein the unmodified immunoglobulin does not significantly bind to said epitope, comprising the steps of: providing a nucleic acid encoding an immunoglobulin comprising at least two structural loops, modifying at least one nucleotide residue of each of said structural loops, transferring said modified nucleic acid in an expression System, expressing said modified immunoglobulin, contacting the expressed modified immunoglobulin with an epitope, and determining whether said modified immunoglobulin binds to said epitope, immunoglobulins produced by such a method and libraries of immunoglobulins. | 02-04-2010 |
| 20100048877 | NOVEL MULTIVALENT IMMUNOGLOBULINS - The present invention provides a multivalent immunoglobulin or part thereof binding specifically to at least two cell surface molecules of a single cell with at least one modification in at least one structural loop region of said immunoglobulin determining binding to an epitope of said cell surface molecules wherein the unmodified immunoglobulin does not significantly bind to said epitope, its use and methods for producing it. | 02-25-2010 |
| 20110046355 | CYTOTOXIC IMMUNOGLOBULIN - The invention relates to a cytotoxic modular antibody with a molecular weight of up to 6 OkD, specifically binding to a cell surface target with a binding affinity of Kd<10 | 02-24-2011 |
| Patent application number | Description | Published |
|---|
| 20090104268 | Nanoparticles Comprising Antigens and Adjuvants, and Immunogenic Structures - Nanoparticles comprising adjuvants and antigens, such as tumour and pathogen antigens, are disclosed and their use in a range of applications such as for the treatment of cancer and infectious diseases. Immunogenic structures based on nanoparticles or antibodies with carbohydrate ligands, and their use for therapeutic and prophylactic purposes, and for the isolation and detection of antibodies directed against the carbohydrate structures. | 04-23-2009 |
| 20090181030 | USE OF A PREPARATION BASED ON AN ANTIBODY DIRECTED AGAINST A TUMOR-ASSOCIATED GLYCOSYLATION - The invention relates to the use of a preparation based on an antibody directed against a tumor-associated glycosylation for preparing a medicament for the prophylactic and/or therapeutic treatment for the reduction or inhibition, respectively, of the growth of tumor cells in a cancer patient, as well as to a pharmaceutical preparation containing an antibody directed against a tumor-associated glycosylation. Moreover, the invention relates to a preparation for pharmaceutical and/or diagnostic use, a diagnostic method and an agent for determining the risk of metastasis formation in a cancer patient, as well as a method of producing a preparation based on a body fluid or tissue, in each case using the antibody directed against a tumor-associated glycosylation. | 07-16-2009 |
| 20100310551 | IMMUNOGENIC, MONOCLONAL ANTIBODY - The invention relates to an immunogenic antibody which comprises at least two different epitopes of a tumor-associated antigen. | 12-09-2010 |
| 20110020331 | N-GLYCOSYLATED ANTIBODY - The invention relates to a monoclonal antibody or derivative or fragment thereof that is derived from a parental monoclonal antibody, that recognizes the Lewis Y antigen, characterized in that the Fc region or region equivalent to the Fc region of said antibody or derivative or fragment thereof carries a bi-sected hybrid type N-glycosylation pattern and that said antibody shows at least 10 fold increased ADCC and at least 10% reduced CDC activity. | 01-27-2011 |
